ABSTRACT Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) also called flozins or gliflozins have been demonstrated to have multi‐system benefits across the endocrine, metabolic, renal and cardiovascular systems. As a result, indications for use of SGLT2i have grown, however, there is limited evidence describing their use in people with CF (pwCF). We describe safe, tolerable and effective use of SGLT2i in three adults with CF. Indications for SGLT2i in our three cases varied. Our first case required it for glycaemic management due to predominantly type 2 diabetes phenotype. The next case had heavy proteinuria due to CF diabetes‐related nephropathy. And the last case had non‐diabetes related nephropathy. All cases tolerated SGLT2i without any side effects. Our findings add to the limited literature on SGLT2i use in pwCF, which will become increasingly relevant given an ageing CF population in the post‐modulator era.
Johnson et al. (2026) studied this question.